azelnidipine
Azelnidipine is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa In 2020. — Wikipedia
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2005 (NCT00134160)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Voltage-gated T-type calcium channelANTAGONIST
Voltage-gated T-type calcium channel antagonist
- L-type calcium channelANTAGONIST
L-type calcium channel antagonist
Voltage-gated L-type calcium channel blocker
Also binds T-type calcium channels.
Chemistry & pharmacology
SMILES
CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1- Mol. weight
- 582.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAzelnidipine ↗
- ChEMBLCHEMBL1275868 ↗
Also known as
- 3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
- 3,5-pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) ester, (+-)-
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- azelnidipine
- calblock
- cs 905
- cs-905
- cs-905
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01819441 | Phase 4 | May 1, 2012 | Peking University |
| NCT01028534 | N/A | Jul 1, 2010 | Kyoto University |
| NCT00454662 | Phase 4 | Apr 1, 2007 | COLM Study Research Organization, Japan Heart Foundation, Keio University, Osaka University |
| NCT00607035 | Phase 4 | May 1, 2006 | Jichi Medical University |
| NCT00294567 | Phase 4 | Dec 1, 2005 | Japan Heart Foundation, Juntendo University |
| NCT00134160 | Phase 4 | Aug 1, 2005 | Fukuoka University, Japan Heart Foundation, OSCAR Study |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Japan Heart Foundation | Academic/Hospital | 3 | 0 | 1 | 2005 |
| COLM Study Research Organization | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Fukuoka University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Jichi Medical University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Juntendo University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Keio University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Kyoto University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Osaka University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| OSCAR Study | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2012 |